Clinical Trial Update: Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 evaluation of 64Cu-DOTA-U3-1287 in subjects with advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Lymphoma
• Sarcoma

Drugs mentioned

• 64Cu-DOTA-U3-1287 (64Cu-DOTA-U3-1287)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma, Sarcoma | Phase 1 | Status: TERMINATED